University Hospitals first in Ohio to treat patients with two FDA approved CAR T cancer therapies
Latest immunotherapies target multiple myeloma and diffuse large B-cell lymphoma
News provided by
Share this article
Share this article
CLEVELAND, May 6, 2021 /PRNewswire/ Oncologists at University Hospitals (UH) have two new powerful tools in the fight against cancer following the announcement that Abecma & Breyanzi, from Bristol Myers Squibb (BMS), are currently being used to treat patients at UH Seidman Cancer Center. Providing these latest CAR T-cell therapies to our patients is just another way UH Seidman Cancer Center is leading the way in immunotherapy, says Ted Teknos, MD, President and Chief Scientific Director of UH Seidman. Last fall, the Wesley Center for Immunotherapy at UH Seidman was named in honor of Kimberly and Joseph Wesley. The Wesley Family donated $10 million to support groundbreaking research to bring new, life-extending immunotherapy treatments to pa